Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized double-blind placebo-controlled study of LIK066 in obesity-associated nonalcoholic steatohepatitis
MOH_2018-02-19_002046Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) and obesity (3 arms), sponsored by Novartis. Primary endpoint: Metabolic and inflammatory biomarkers. Started Feb 2018; status: completed.
02
Drugs
licogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)obesity
Beyond the preview
Go deeper on MOH_2018-02-19_002046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-19_002046.